140 related articles for article (PubMed ID: 15726024)
21. Probable association between ziprasidone and worsening hypertension.
Villanueva N; Markham-Abedi C; McNeely C; Diaz FJ; de Leon J
Pharmacotherapy; 2006 Sep; 26(9):1352-7. PubMed ID: 16945059
[TBL] [Abstract][Full Text] [Related]
22. Ziprasidone-induced spontaneous orgasm.
Boora K; Chiappone K; Dubovsky S; Xu J
J Psychopharmacol; 2010 Jun; 24(6):947-8. PubMed ID: 19164500
[TBL] [Abstract][Full Text] [Related]
23. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
Mauri MC; Colasanti A; Rossattini M; Volonteri LS; Dragogna F; Fiorentini A; Fiorentini A; Valli A; Papa P
Pharmacopsychiatry; 2007 May; 40(3):89-92. PubMed ID: 17541882
[TBL] [Abstract][Full Text] [Related]
24. Ziprasidone induction of hypomania in depression?
Davis R; Risch SC
Am J Psychiatry; 2002 Apr; 159(4):673-4. PubMed ID: 11925314
[No Abstract] [Full Text] [Related]
25. Serial plasma prolactin levels in neuroleptic-induced galactorrhea: a case report.
Gioia P; Asnis G
J Clin Psychiatry; 1988 Jan; 49(1):29-31. PubMed ID: 2891689
[TBL] [Abstract][Full Text] [Related]
26. Multi-drug overdose risperidone, ziprasidone, valproate, trihexyphenidyl, and clonazepam.
Rajkumar AP; Jebaraj P; Tharyan P
J Assoc Physicians India; 2007 Feb; 55():146-8. PubMed ID: 17571746
[TBL] [Abstract][Full Text] [Related]
27. Ziprasidone monotherapy in bipolar II depression: an open trial.
Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
[TBL] [Abstract][Full Text] [Related]
28. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article.
Scott LK; Green R; McCarthy PJ; Conrad SA
J Neurosurg Pediatr; 2009 Jun; 3(6):484-7. PubMed ID: 19485732
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
30. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
31. Ziprasidone in the treatment of delayed carbon monoxide encephalopathy.
Hu MC; Shiah IS; Yeh CB; Chen HK; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):755-7. PubMed ID: 16581170
[TBL] [Abstract][Full Text] [Related]
32. Rhabdomyolysis after correction of hyponatremia in psychogenic polydipsia possibly complicated by ziprasidone.
Zaidi AN
Ann Pharmacother; 2005 Oct; 39(10):1726-31. PubMed ID: 16131536
[TBL] [Abstract][Full Text] [Related]
33. Ziprasidone-associated mania: a review and report of 2 additional cases.
Keating AM; Aoun SL; Dean CE
Clin Neuropharmacol; 2005; 28(2):83-6. PubMed ID: 15795551
[TBL] [Abstract][Full Text] [Related]
34. The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases.
Eker SS; Sarandol A; Akkaya C; Sivrioglu EY; Kirli S
J Psychopharmacol; 2009 Nov; 23(8):993-6. PubMed ID: 18635710
[TBL] [Abstract][Full Text] [Related]
35. Urticaria and angio-oedema due to ziprasidone.
Akkaya C; Sarandol A; Aydogan K; Kirli S
J Psychopharmacol; 2007 Jul; 21(5):550-2. PubMed ID: 17446198
[TBL] [Abstract][Full Text] [Related]
36. Pregnancy and atypical antipsychotics.
Ruzić K; Dadić-Hero E; Knez R; Medved P; Petrić D
Psychiatr Danub; 2009 Sep; 21(3):368-70. PubMed ID: 19794358
[TBL] [Abstract][Full Text] [Related]
37. Ziprasidone-induced hyperprolactinemia: a case report.
Citil DY; Selçuk E; Karlidağ R; Unal S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):905-6. PubMed ID: 18276052
[No Abstract] [Full Text] [Related]
38. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
39. Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats.
Fell MJ; Gibson R; McDermott E; Sisodia G; Marshall KM; Neill JC
Behav Brain Res; 2005 May; 160(2):338-43. PubMed ID: 15863230
[TBL] [Abstract][Full Text] [Related]
40. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
